HGEN News and Press, Humanigen Inc. From 03/29/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cruise stocks are taking on water Monday after the Centers for Disease Control and Prevention (CDC) dashed hopes for sailing to resume sooner than expected. Source: Shutterstock.com Cruise companies were pushing for...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Humanigen (NASDAQ: HGEN ) stock are taking off on Monday morning after the firm reported major news for those suffering from the novel coronavirus. Source: luchschenF / Shutterstock.com The biopharma...

Universe Pharmaceuticals (UPC) +113%.Humanigen (HGEN) +61% on positive Phase 3 data for COVID-19 therapy.Cyanotech Corporation (CYAN) +48%.Big Rock Partners Acquisition (BRPA) +42%.SeaChange International (SEAC) +34% on multi-million-dollar contract with broadband service provider.F...

Humanigen (HGEN) has added ~43.8% in the pre-market after announcing that its lead drug candidate against COVID-19, lenzilumab achieved the primary endpoint in a Phase 3 study in patients who were hospitalized with COVID-19 pneumonia.In the randomized trial, the patients w...

Lenzilumab improved the relative likelihood of survival without need for invasive mechanical ventilation (IMV) by 54%, achieving the primary endpoint of the Phase 3 study Clinical improvement was observed over and above other treatments, including steroids and/or remdesivir ...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, announced that management will host a confer...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, announced today that its board of di...

The following slide deck was published by Humanigen, Inc. in conjunction with this event. For further details see: Humanigen (HGEN) Presents At Oppenheimer 31st Annual Healthcare Conference - Slideshow

Humanigen (HGEN): Q4 GAAP EPS of -$0.63 beats by $0.04.Revenue of $312kCash and cash equivalents of $67.7MPress Release For further details see: Humanigen EPS beats by $0.04

Humanigen (HGEN) has obtained a term loan facility from Hercules Capital (HTGC) for up to $80M of secured debt financing.“The term loan facility provides working capital to support the production of lenzilumab, strengthens our balance sheet and increases our financial flexibility as we...